Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
Become a Member | Sign in
Home>News>This Article

Cevec Announces that CAP Cells Produce High Titers of RSV Vaccine

Published: Wednesday, March 12, 2014
Last Updated: Wednesday, March 12, 2014
Bookmark and Share
Company announces excellent data from an evaluation program for RSV vaccine production.

CEVEC Pharmaceuticals has announced excellent data from an evaluation program for production of RSV vaccine in CAP cells. The data were obtained in a collaborative project with Paragon Bioservices Inc., a leading US biopharmaceutical contract manufacturer (CMO), and show that CAP cells were able to produce very high titers of RSV.

Moreover and in contrast to other production systems, RSV produced in CAP cells show high-level of functional G-protein resulting in a very effective RSV vaccine with positive impact on attenuated-vaccine studies.

With these data CAP cells prove again that they are an excellent tool as an expression system for different vaccines, meeting the highest regulatory demands and process requirements.

Even though many common diseases of childhood can now be prevented by early vaccination, currently there is still no vaccine approved to prevent RSV infection.

Worldwide it is estimated that RSV is responsible for a very high number of hospitalized infants and nearly seven percent of deaths in babies in their first year of life.

“Again CAP cells prove their enormous potential and significant advantages over many currently used production systems for vaccines,” commented Dr. Rainer Lichtenberger, COO / CFO of CEVEC.

Dr. Lichtenberger continued, “Next to Cytomegalovirus, Influenza and others, this is another striking example that CAP cells can efficiently propagate disease relevant human viruses. We were very pleased to work with Paragon on this project and benefited from their experience in vaccine production. This collaboration was extremely pleasant and successful.”

“The data obtained here will further help to position our CAP technology as unique production system also in the vaccine market”, added Wolfgang Kintzel, CEO of CEVEC. “CAP cells have already proven their immense potential for the production of therapeutic proteins in preclinical settings and in clinical trials. They are currently the only independent human cell line available for the production of such a broad array of biopharmaceuticals including both, vaccines and proteins.”

Paragon’s CEO Marco Chacón agrees, “This teamwork pays not only for CEVEC, but also for Paragon. With use of CAP cells we can offer our customers a unique production system to meet the challenges of their vaccine target. With this highly ambitious project we have again proven our expertise in this competitive business.”

CAP cells are an immortalized cell line derived from primary human amniocytes that meet the highest ethical and regulatory standards.

CAP cells grow in serum-free suspension culture and allow for stable production of proteins and viruses / vaccines.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Antibody Treatment Efficacious in Psoriasis
An experimental, biologic treatment, brodalumab, achieved 100 percent reduction in psoriasis symptoms in twice as many patients as a second, commonly used treatment, according to the results of a multicenter clinical trial led by Mount Sinai researchers.
Promising Drug Candidate to Treat Chronic Itch
In a new study, scientists from the Florida campus of The Scripps Research Institute (TSRI) describe a class of compounds with the potential to stop chronic itch without the adverse side effects normally associated with medicating the condition.
Escape Prevention
Studying flu virus structure brings us a step closer to a permanent vaccine.
13 Ways to Stop an Unseen Force from Disrupting Weighing
Download a free Mettler Toledo paper to discover how to halt static’s negative effects before the next weigh-in.
Inroads Against Leukaemia
Potential for halting disease in molecule isolated from sea sponges.
A New Single-Molecule Tool to Observe Enzymes at Work
A team of scientists at the University of Washington and the biotechnology company Illumina have created an innovative tool to directly detect the delicate, single-molecule interactions between DNA and enzymatic proteins.
Milestone Single-Biomolecule Imaging Technique May Advance Drug Design
The first nanometer resolved image of individual tobacco mosaic virions shows the potential of low-energy electron holography for imaging biomolecules at a single particle level; a milestone in structural biology and a potential new tool for drug design.
Researchers Discover A New Mechanism of Proteins to Block HIV
Certain IFITM proteins block and inhibit cell-to-cell transmission of HIV.
Opening the Door to Safer, More Precise Cancer Therapies
New method regulates when, and how strongly, cancer-killing therapeutic T cells are activated.
Vaccination On The Horizon For Severe Viral Infection Of The Brain
Researchers from the University of Zurich and the University Hospital Zurich reveal possible new treatment methods for a rare, usually fatal brain disease.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos